Cita APA (7a ed.)

Liu, Q., Tan, C., Yi, L., Wan, X., Peng, L., Li, J., . . . Zeng, X. (2021). Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer. Public Library of Science (PLoS).

Cita Chicago Style (17a ed.)

Liu, Qiao, Chongqing Tan, Lidan Yi, Xiaomin Wan, Liubao Peng, Jianhe Li, Xia Luo, y Xiaohui Zeng. Cost-effectiveness Analysis of Pembrolizumab Plus Chemotherapy as First-line Therapy for Extensive-stage Small-cell Lung Cancer. Public Library of Science (PLoS), 2021.

Cita MLA (8a ed.)

Liu, Qiao, et al. Cost-effectiveness Analysis of Pembrolizumab Plus Chemotherapy as First-line Therapy for Extensive-stage Small-cell Lung Cancer. Public Library of Science (PLoS), 2021.